TruScreen Ultra

  • 2017

  • Product
    Medical and Scientific

Designed By:

  • TruScreen Pty Ltd
  • ide Group

Commissioned By:

TruScreen Pty Ltd

Designed In:


TruScreen Ultra is a wireless handheld cervical cancer screening device that provides patients with immediate, accurate results. It offers a new approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructure.

view website
Buy online

  • MORE
  • Cervical cancer is the second largest cause of deaths due to cancer in women and early diagnosis is a crucial element in reducing the number of deaths from the disease. Based on studies involving more than 10,000 women worldwide with the TruScreen device, women reported preferring the immediate result and reported significantly less pain, pressure and scraping than experienced with the spatula or brushes used to collect cells from the cervix in cytology based screening. Unlike a traditional Pap test, TruScreen does not require the collection of tissue samples which helps minimise patient discomfort and increases the overall chances of the patient returning for a repeat screen.

  • According to World Health Organisation, more than 80% of cervical cancer cases occur in developing countries, yet women in these areas often do not have access to prevention, screening and treatment services. TruScreen features an objective, self-checking digital system that can be used with minimal training of medical or paramedical staff, making the device simple and safe to use for physicians across cultures. The device also provides immediate, accurate results without the reliance on expensive laboratory infrastructure. This enables significant cost savings to be translated into greater accessibility for women to receive the lifesaving procedure.

  • TruScreen is the only objective, immediate optical-electrical test currently available. The technology works by detecting pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. TruScreen technology has been found to be twice as sensitive as the Pap test and significantly more sensitive than HPV DNA testing at defining high grade cervical lesions in a real world setting. As well as high accuracy, TruScreen provides an instant report, thus preventing the risk of losing contact with the patient because of the delay associated with transportation of samples to laboratories for analysis and reporting.

  • TruScreen Ultra was designed with the knowledge that the device could be used on as many as 20 patients per day. Based on real world clinical feedback and tested on-site with a Medical Advisory Committee, the design of the device enables specialists to test higher volumes of patients per day with greater ease and comfort. The handpiece caters for a spectrum of hand sizes, enabling handling around the body.

    TruScreen Ultra was designed above all to be easy to use. The Graphical User Interface design is a simple step by step process requiring minimal training and user input. Results are clearly displayed on screen and wirelessly downloaded to software on a PC, ensuring records are not lost. The device automatically switches on when docked and powers down when not in use, eliminating the need for any physical buttons.

    TruScreen Ultra features wireless connectivity, wireless charging and a custom designed cradle. Once the device is docked, charging initiates automatically and the cradle probe tip is protected from damage. The design also enables easy transfer of the device from room to room to help support physicians in high volume testing scenarios.

    TruScreen Ultra includes a Single Use Sensor (SUS) component which prevents cross-contamination between patients. The tip of the SUS incorporates a highly critical electroplated lens to provide the electrical and optical interface between the device and the cervical tissue, ensuring the patient is protected from the potential harm of cross-contamination.